Rate Control in Atrial Fibrillation II

• Status: Active, not recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The RATAF II study is a randomized, prospective, parallel group study, designed to compare the effects of two different drug regimens for rate control in permanent AF (atrial fibrillation). We will investigate on the difference in effects on exercise capacity, biomarkers (NT-proBNP (N-terminal pro-brain natriuretic peptide), troponins, hs-CRP), heart rate, echocardiographic measurements and symptoms.

Our main hypothesis is that six months' treatment with the calcium channel blocker diltiazem will lower NT-proBNP and increase exercise capacity (peak VO2) compared to treatment with the beta blocker metoprolol in permanent AF.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asker & Baerum Hospital
• Collaborators: Helse Sor-Ost; Vestre Viken Hospital Trust
• Treatments: Adrenergic beta-1 Receptor Antagonists; Diltiazem; Metoprolol; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents

Criteria

Inclusion Criteria:

• Above 18 years of age

• Symptomatic, permanent AF of at least three months duration

• Resting heart rate ≥80 bpm

• Signed informed consent

Exclusion Criteria:

• Congestive heart failure

• Ischemic heart disease

• Hypotension (Systolic blood pressure <100 mmHg)

• Treatment with class I or III antiarrhythmic drugs

• Severe hepatic or renal failure

• Pregnancy or lactation

• Hypersensitivity or contradictions to study drugs

• Atrio-ventricular conduction disturbances

• Thyrotoxicosis

• Life limiting disease or substance abuse which may affect participation